FluoGuide is trading at SEK 32.80 (+5.47%) after positive Phase 2 CT-005 results highlighted in its August 25, 2026 interim report.

  • The report identified 0.30 mg/kg as the optimal dose and noted good tolerability.
  • FluoGuide received FDA authorization for CT-006, activated its first U.S. site, and began its first pivotal U.S. registration-supporting study.
  • Despite wider losses and cash use, these clinical milestones appear to be the clearest catalyst.